PMV Pharmaceuticals (PMVP) Projected to Announce Earnings on Thursday

PMV Pharmaceuticals (NASDAQ:PMVP) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.38) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its earnings results on Tuesday, May 12th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.07. On average, analysts expect PMV Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PMV Pharmaceuticals Price Performance

PMVP stock opened at $1.07 on Thursday. PMV Pharmaceuticals has a 1-year low of $1.02 and a 1-year high of $1.88. The business has a fifty day moving average price of $1.21 and a 200-day moving average price of $1.27. The stock has a market capitalization of $57.06 million, a P/E ratio of -0.72 and a beta of 1.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd increased its position in shares of PMV Pharmaceuticals by 144.3% during the 4th quarter. XTX Topco Ltd now owns 104,485 shares of the company’s stock valued at $131,000 after purchasing an additional 61,723 shares during the last quarter. Tang Capital Management LLC boosted its holdings in shares of PMV Pharmaceuticals by 3.2% in the fourth quarter. Tang Capital Management LLC now owns 4,940,000 shares of the company’s stock worth $6,175,000 after buying an additional 154,799 shares during the last quarter. Bridgeway Capital Management LLC boosted its holdings in shares of PMV Pharmaceuticals by 33.7% in the fourth quarter. Bridgeway Capital Management LLC now owns 428,853 shares of the company’s stock worth $536,000 after buying an additional 108,200 shares during the last quarter. Public Employees Retirement System of Ohio grew its position in PMV Pharmaceuticals by 349.7% during the fourth quarter. Public Employees Retirement System of Ohio now owns 27,434 shares of the company’s stock valued at $34,000 after buying an additional 21,334 shares during the period. Finally, Squarepoint Ops LLC grew its position in PMV Pharmaceuticals by 101.8% during the fourth quarter. Squarepoint Ops LLC now owns 26,502 shares of the company’s stock valued at $33,000 after buying an additional 13,367 shares during the period. 90.20% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Weiss Ratings downgraded PMV Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Evercore upgraded shares of PMV Pharmaceuticals to a “strong-buy” rating in a research note on Monday, April 13th. LADENBURG THALM/SH SH initiated coverage on shares of PMV Pharmaceuticals in a report on Wednesday, July 8th. They set a “buy” rating and a $3.00 price target on the stock. Finally, Oppenheimer reduced their price target on shares of PMV Pharmaceuticals from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.